Physician profile
Thomas Hogan
NPI 1265472823
$16,547.43
in general payments reported to CMS, 2019-2025
71 companies · $2,701 in 2025
The $2,701 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,536 · 2020: $1,708 · 2021: $2,105 · 2022: $2,400 · 2023: $2,824 · 2024: $2,274 · 2025: $2,701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,799.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,561.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $2,134.24 | 2019-2025 | |
| Abbvie INC. | $1,663.51 | 2021-2025 | |
| Amgen INC. | $1,186.67 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $1,063.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $977.38 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $456.89 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $448.72 | 2019-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $429.18 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.88 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $413.78 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $363.25 | 2022-2025 | |
| Allergan, INC. | $319.40 | 2019-2020 | |
| Esperion Therapeutics, INC. | $291.25 | 2020-2024 | Nexletol |
| Boston Scientific Corporation | $225.91 | 2019-2025 | Watchman Flx, General - Pain Management |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.